Evidence map›Paper›PMID 40556963›Full record

ArticleWorld journal of oncology2025

Assessing the Impact of

Ginanda Putra Siregar, Ida Parwati, Ferry Safriadi, Tjahjodjati Tjahjodjati

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ginanda Putra SiregarDoctoral Study Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Ida ParwatiDepartment of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Ferry SafriadiDepartment of Urology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Tjahjodjati TjahjodjatiDepartment of Urology, Faculty of Medicine, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: One of the most common cancers is bladder cancer, characterized by a high mortality rate and a high incidence of recurrence. An identified susceptibility factor for bladder cancer is the presence of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor ( Methods: This pilot study was conducted to uncover the association between the SNP Results: This study showed a significant association between the Conclusion: This pilot study suggests that

Indexed as

Bladder cancerRisk factorSingle nucleotide polymorphismVEGF

Identifiers

PMID40556963
PMCPMC12185121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.